Genomics of Drug Sensitivity in Cancer
Cell Line: SHP-77
Link to Cell Model Passport
Drug | Targets | Z score |
|---|---|---|
| Vismodegib | SMO | -2.27464 |
| Fulvestrant | ESR | -1.96583 |
| Picolinici-acid | Inflammatory related | -1.7876 |
| Telomerase Inhibitor IX | Telomerase | -1.74592 |
| AGI-6780 | IDH2 R140Q mutant | -1.69195 |
| GSK-LSD1-2HCl | LSD1 | -1.64462 |
| GSK2578215A | LRRK2 | -1.51106 |
| A-366 | EHMT1, EHMT2 | -1.4547 |
| SGC-CBP30 | EP300, CBP | -1.43217 |
| GSK2801 | -1.4068 | |
| 123138 | -1.40516 | |
| EPZ004777 | DOT1L | -1.40123 |
| Dacarbazine | CP11A | -1.37442 |
| Veliparib | PARP1, PARP2 | -1.368 |
| Dihydrorotenone | -1.36615 | |
| LGK974 | PORCN | -1.36277 |
| PCI-34051 | HDAC8, HDAC6, HDAC1 | -1.35017 |
| alpha-lipoic acid | Metabolism | -1.34783 |
| Wnt-C59 | PORCN | -1.33356 |
| UMI-77 | MCL1 | -1.29871 |
| EHT-1864 | RAC1, RAC2, RAC3 | -1.28944 |
| GSK1904529A | IGF1R, IR | -1.19886 |
| TW 37 | BCL2, BCL-XL, MCL1 | -1.19315 |
| Fulvestrant | ESR | -1.1781 |
| IRAK4_4710 | IRAK4 | -1.17013 |
The Genomics of Drug Sensitivity in Cancer Project is a collaboration
between the Cancer Genome Project
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
https://www.cancerrxgene.org/cellline/SHP-77/724872
Contact us | Cookies policy | Terms & Conditions.
This site is hosted by the Wellcome Sanger Institute.